PubMed Health⌕ Search

PubMed · 11666825

Ring Systems Containing Anionic and Cationic Gallium Centers: Structural and Bonding Considerations.

Abstract

The metathetical reaction of 2-(dimethylamino)benzyllithium (Bz(N)Li) with GaCl(3) afforded the salt [Bz(N)(2)Ga][GaCl(4)] (4), the X-ray crystal structure of which revealed a four-coordinate cationic gallium center featuring two Ga-C sigma-bonds and two N-->Ga dative bonds. (Crystal data for 4: monoclinic, space group P2(1)/n, a = 11.519(2) Å, b = 18.254(4) Å, c = 12.506(3) Å, beta = 117.40(3) degrees, V = 2334.6(9) Å(3), Z = 4, R = 0.545). Two Ga.Cl interionic contacts, while somewhat long, are sufficiently strong to render the geometry of 4(+)() roughly midway between tetrahedral and octahedral. Treatment of 1,4-di-tert-butyl-1,4-diazabutadiene (DAB) with 2 equiv of GaCl(3) afforded [(DAB)GaCl(2)][GaCl(4)] (7), which, by means of X-ray analysis, was shown to possess a cation (7(+)()) with localized C=N bonds and N-->Ga dative interactions with a [GaCl(2)](+) moiety. (Crystal data for 7: orthorhombic, space group Pbca, a = 11.882(2) Å, b = 17.289(3) Å, c = 20.424(4) Å, V = 4195.5(11) Å(3), Z = 8, R = 0.460). The structure of 7(+)() is relevant to discussions of the bonding in both neutral DAB complexes of the group 13 elements and the skeletally isoelectronic anion [Me(4)C(4)GaCl(2)](-) (9(-)()). The structure of the [NEt(4)](+) salt of the latter (9) has been determined by X-ray diffraction. (Crystal data for 9: monoclinic, space group P2(1)/n, a = 9.967(1) Å, b = 13.073(2) Å, c = 15.345(2) Å, beta = 96.76(1) degrees, V = 1985.5(4) Å(3), Z = 4, R = 0.721).

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jason A. C. Clyburne, Robert D. Culp, Smuruthi Kamepalli, Alan H. Cowley, Andreas Decken. 1996-11-06. Ring Systems Containing Anionic and Cationic Gallium Centers: Structural and Bonding Considerations.. https://doi.org/10.1021/ic960647d

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗